On this episode we sit down with Dr. David Stamler (CEO) and Daniel Claassen (CMO) of Alterity Therapeutics to discuss their drug candidate, ATH434, phase 2 results and path to phase 3 trials to treat MSA.
🎧 Spotify: https://t.co/q9sqCN8mP2
📺 YouTube: https://t.co/ckLvx5UeMk
The cement industry accounts for ~8% of global emissions.
Aaron Banks, Executive Chairman of Green360 Technologies, discussed what the company's building and why it matters to build a sustainable future.
🎧 Spotify: https://t.co/K4NWyuXr5V
📺 YouTube: https://t.co/xrwgoReymr
Stroke is one of the most time-critical emergencies in medicine.
On the latest episode of Vantage Point, Scott Kirkland, CEO of EMVision Medical Devices, discusses how their technology could save lives.
🎧 Spotify: https://t.co/Za4wqIyVA0
📺 YouTube: https://t.co/0ZUrKj4PYy
Some of the best small-cap investing stories are built on patience.
On the latest episode of Vantage Point, Leo Barry walks through Fairview’s long history with Codan Limited.
Full episode streaming now.
🎧 Spotify: https://t.co/tP9YftdiWH
📺 YouTube: https://t.co/yqo4grj1qw
Chris Judd returns to Vantage Point.
Cerutty Macro Fund has delivered ~25% annualised returns since June 2023. We cover #gold, #energy and #AI infrastructure, how he navigates volatility, and why the fund is built for returns, not scale.
Link in the comments 🎧
“We’ve followed through on every single thing we said we’d do.”
Blackpearl $BPG CEO Nick Lissette talks execution, ARR milestones and a high-growth acquisition — plus a $50M ARR target in 3 years.
Full episode👇
Spotify: https://t.co/HrpDxqnfop
YouTube: https://t.co/mrY7URxCdq
🎙️ Latest episode of @VantagePointNWR features Peter De Leo, MD & CEO of @Lycopodium (ASX: $LYL) on how the company delivers some of the world’s leading resources and infrastructure projects.
🎧 Spotify: https://t.co/FMTaV0Q2uI
📺 YouTube: https://t.co/neAviTeSnG